GIM
RLMD icon

Guild Investment Management’s Relmada Therapeutics RLMD Stock Holding History

Guild Investment Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-73,596
Closed -$221K – 54
2024
Q2 		$221K Sell
73,596
-117,404
-61% -$425K 0.25% 46
2024
Q1 		$888K Sell
191,000
-21,100
-10% -$102K 1.14% 26
2023
Q4 		$878K Buy
212,100
+6,800
+3% +$20.1K 1.39% 27
2023
Q3 		$616K Buy
205,300
+93,750
+84% +$278K 1.03% 33
2023
Q2 		$274K Buy
111,550
+7,650
+7% +$21.1K 0.39% 49
2023
Q1 		$235K Buy
+103,900
New +$358K 0.36% 49

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Guild Investment Management's RLMD Position: Q3 2024 in Review

Guild Investment Management sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 73,596 shares — an estimated $221K sold.

Guild Investment Management first reported a position in RLMD in Q1 2023 and held it in 6 quarters. The position peaked at $888K in Q1 2024. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Guild Investment Management reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Guild Investment Management sold 73,596 Relmada Therapeutics shares in Q3 2024, an estimated $221K.
  • Guild Investment Management first reported a position in Relmada Therapeutics in Q1 2023 and held it in 6 quarters.
  • Guild Investment Management's Relmada Therapeutics position peaked at $888K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Guild Investment Management's 13F filing for Q3 2024, filed 9 Oct 2024.